Back to results

CompletedPhase 2

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

NCT02537470

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Advanced Arizona Clinical Research

Tucson, Arizona, United States

+18 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2015-07
Enrollment: 191 participants
Sponsor: BHV Pharma
Purpose: treatment

Locations (19)

Advanced Arizona Clinical ResearchTucson, Arizona, United States
Long Beach Clinical TrialsLong Beach, California, United States
Long Beach Center for Clinical ResearchLong Beach, California, United States
National Research InstituteLos Angeles, California, United States
Orange County Research CenterTustin, California, United States
Diablo Clinical ResearchWalnut Creek, California, United States
Chase Medical ResearchWaterbury, Connecticut, United States
Medical Research UnlimitedHialeah, Florida, United States
Progressive Medical ResearchPort Orange, Florida, United States
Meridien ResearchTampa, Florida, United States
eStudySite, Las VegasLas Vegas, Nevada, United States
Comprehensive Clinical ResearchBerlin, New Jersey, United States
Albuquerque Clinical Trials, IncAlbuquerque, New Mexico, United States
Mountain View Clinical ResearchGreer, South Carolina, United States
New Phase Research & DevelopmentKnoxville, Tennessee, United States
Austin Center for Clinical ResearchAustin, Texas, United States
Padre Coast Clinical ResearchCorpus Christi, Texas, United States
Juno Research, LLCHouston, Texas, United States
Wasatch Clinical ResearchSalt Lake City, Utah, United States

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes — TrialFind